Lilly And Novo Nordisk Shape Up For Obesity Treatment Battle Of The Heavyweights
Key Phase III Readouts Soon
Eli Lilly’s Mounjaro looks set to gain US approval for obesity this year and upcoming Phase III data could help it eclipse the huge success of Novo Nordisk’s Wegovy.
You may also be interested in...
Company says its new API production facility in Denmark will come online in 2029 and help meet demand for pipeline products in serious chronic diseases. Novo is currently contending with supply crunches for its semaglutide products.
When the first non-alcoholic steatohepatitis drugs reach market, the health cost watchdog says payers will be justified in setting step-therapy including weight-management efforts, while early prescribing should be by specialists.
A 50mg dose of oral semaglutide showed similar weight loss to the weekly injectable version that Novo already markets as Wegovy.